The big issues are still the rising cost of coverage and the impact that rising costs have on health plan membership
Premiums for employer-sponsored health insurance rose to $13,375 annually for family coverage this year-with employees on average paying $3,515 and employers paying $9,860, according to the 2009 Employer Health Benefits Survey released by the Kaiser Family Foundation and the Health Research & Educational Trust.
According to Jordan Battani, principal at CSC, a consulting and outsourcing company, in Falls Church, Va., for managed care executives, the big issues are still the rising cost of coverage and the impact that rising costs have on health plan membership.
“Although the increases this year are lower than in preceding years-they still far surpass general inflation-which was negative,” Battani says. “As general economic conditions decline, the ability of individual consumers and employer purchasers to withstand price increases erodes, and they may exit the market.”
Another factor, particularly as it relates to employer purchasers who compete in an increasingly global economy, is that extraordinary costs in the market place U.S. employers at a competitive disadvantage, according to Battani.
“Again, these employer purchasers may decide to exit the market-either by dropping employer sponsored coverage, or in a more dramatic fashion, by abandoning the U.S. labor force entirely,” Battani says.
Employers and managed care executives must continue to focus on addressing the underlying costs of healthcare, and the underlying inflation that drives premium. Of particular importance is the direct and indirect healthcare costs associated with long term chronic disease, Battani says.
Managed care executives should make efforts to support these workplace programs, she says, and perhaps design value-added services for employers that will assist them in promoting expanding and maintaining them.
“At the same time, it is probably time to re-examine the strategy of shifting costs to consumers, either through high-deductible plans or in the form of copays and coinsurance,” Battani says. “These strategies may have been effective in moderating the growth of employer premium costs, but this study suggests that for many consumers they are proving onerous or unsupportable on an individual basis.”
FDA Updates for the Week of Sept. 25, 2023
September 30th 2023The FDA has approved several new therapies this week, including a new two-component Pompe therapy, an extended-release drug for major depression without sexual side effects, and an eye drop for drug-induced dilation. Additionally, the agency has set review dates for several products, including odronextamab for blood cancers, sotatercept for pulmonary arterial hypertension, and Dupixent in young children with eosinophilic esophagitis.
Read More
Mostafa Kamal Talks Prime Therapeutics, Magellan Rx Integration, the Organization's Trajectory, More
September 13th 2023Managed Healthcare Executive's Managing Editor Peter Wehrwein, and Editor Briana Contreras, had a discussion in July with Mostafa Kamal, president and CEO of Prime Therapeutics, an organization in which Kamal acquired this position that same month.
Listen
In the Scope of Virtual Health and the Future of “Website” Manner, Per Ateev Mehrotra
August 10th 2023Briana Contreras, an editor of Managed Healthcare Executive, had the pleasure of catching up with MHE Editorial Advisory Board Member, Ateev Mehrotra, MD, MPH, who is a professor of healthcare policy at Harvard Medical School and an Associate Professor of Medicine and Hospitalist at Beth Israel Deaconess Medical Center.
Listen
Gene Therapy for Hemophilia As a ‘Paradigm Shift’
September 28th 2023Roctavian for hemophilia A and Hemgenix for hemophilia B could spare some patients from treatment that involves intravenous infusions of clotting factors several times a week. But a hemophilia expert cautions that the high-priced gene therapies aren’t a cure and that the reprieve won’t last a lifetime.
Read More
Chances of Developing Gout Are Higher for Patients With IBD
September 28th 2023Study links inflammatory bowel disease diagnosis to increased gout risk, with Crohns disease and ulcerative colitis linked to 68% and 38% increases in likelihood of developing gout, respectively, relative to counterparts without IBD.
Read More
2 Clarke Drive
Cranbury, NJ 08512